Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma

Summary

This is a multi center, open-label, single dose, safety study. Approximately 9 to 15 participants with open-angle glaucoma are assigned into 3 sequential dose-levels and will receive ANX007 administered as single, IVT injections.

Timeline

Start

2018-03-23

Primary completion

2018-08-03

Completion

2018-08-03

Drugs

Indications